Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Drug Safety Remains Front and Center In Chromium Capsule Scandal

This article was originally published in The Gold Sheet

Executive Summary

China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.

You may also be interested in...



Dismissing Requests of World’s Gelatin Makers, FDA Asks USP to Add Tests for Melamine to Monograph

Undeterred by arguments from gelatin manufacturers that there is no economic motivation to put melamine in gelatin, FDA asks USP to require additional testing for the potential adulterant.

Dismissing Requests of World’s Gelatin Makers, FDA Asks USP to Add Tests for Melamine to Monograph

Undeterred by arguments from gelatin manufacturers that there is no economic motivation to put melamine in gelatin, FDA asks USP to require additional testing for the potential adulterant.

Hit Collaterally By Popular Backlash Following Vaccine Scandals, China's Sinovac Could Exploit High Quality Standards To Emerge As Winner

BEIJING - Despite being hit by a succession of vaccine scandals and resulting public fears of domestically produced biologics, China's leading vaccine developer could ultimately emerge as a more powerful player due to its sterling reputation in a field of tarnished competitors

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel